摘要
目的 观察原发性肝癌（PLC）患者血清中可溶性B7-H4水平以及介入治疗和手术治疗对其表达的影响.方法 酶联免疫吸附试验（ELISA）法检测32例正常人以及62例PLC患者血清可溶性B7-H4水平,并比较18例Ⅰ期PLC患者手术前后以及25例Ⅱ期PLC患者介入治疗前后血清可溶性B7-H4水平.结果 PLC患者血清可溶性B7-H4水平[（46.83±9.98） μg/L]明显高于正常对照组[（30.24±6.43） μg/L,P＜0.01],血清可溶性B7-H4水平与PLC患者性别、年龄无明显相关,与临床分期明显相关;Ⅲ期[（53.67±10.57） μg/L]明显高于Ⅱ期[（47.32±7.99） μg/L]、Ⅱ期明显高于Ⅰ期[（40.04±8.50） μg/L]、Ⅰ期明显高于正常对照组,两两比较差异有统计学意义（P＜0.05）;手术后PLC患者血清可溶性B7-H4水平[（35.49±8.54） μg/L]明显低于手术前[（40.04±8.50） μg/L]、介入治疗后PLC患者血清可溶性B7-H4水平[（45.02±7.84） μL]明显低予介入治疗前[（47.32±7.99） μg/L],两者差异有统计学意义（P＜0.01）.结论 检测血清可溶性B7-H4有助于监测PLC治疗效果.
Objective To detect the serum soluble B7-H4 （sB7-H4） level of patients with primary liver carcinoma （PLC）,and to investigate the effects of interventional therapy and operation on it.Methods Enzyme linked immunosorbent assay （ELISA） were available to detect the level of serum sB7-H4 in 62 cases of patients with PLC and 32 cases of normal control subject,compared with 18 cases stage Ⅰ of patients with PLC pre-and post-operation,25 cases stage Ⅱ of patients with PLC pre-and postinterventional therapy.Results The level of serum sB7-H4 were elevated in all subgroups of patients with PLC [（46.83 ±9.98） μg/L] compared to the controls [（30.24 ±6.43） μg/L,P 〈0.01],serum sB7-H4 was not correlated sex and age,and with clinical stage; the serum sB7-H4 level in stage Ⅲ [（53.67 ± 10.57） μg/L] was higher in comparison with stage Ⅱ [（47.32 ±7.99） μg/L],in stage Ⅱ it was higher than that in stage Ⅰ [（40.04 ±8.50） μg/L],and in stage Ⅰ it was higher than that in normal control subject （P 〈 0.05）,the serum sB7-H4 levels were remarkably reduced in patients with PLC after operation or interventional therapy （P 〈0.01）.Conclusion The serum sB7-H4 could be taken as an effective indicator monitoring the treatment effect for PLC.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2014年第11期2554-2555,共2页
Chinese Journal of Experimental Surgery
